Abbott Laboratories (NYSE:ABT) vs. Organigram Global (NASDAQ:OGI) Head to Head Comparison

Abbott Laboratories (NYSE:ABT) and Organigram Global (NASDAQ:OGI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Profitability

This table compares Abbott Laboratories and Organigram Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	9.75%	18.04%	9.09%
Organigram Global	28.14%	-13.39%	-8.67%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Abbott Laboratories and Organigram Global, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0	5	21	2	2.89
Organigram Global	0	1	2	0	2.67

Abbott Laboratories presently has a consensus price target of $118.32, suggesting a potential upside of 7.54%. Given Abbott Laboratories’ stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Organigram Global.

Insider & Institutional Ownership

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Abbott Laboratories and Organigram Global”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33 billion	4.29	$6.52 billion	$2.68	41.05
Organigram Global	$185.07 million	0.67	-$17.70 million	$0.46	1.91

Abbott Laboratories has higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Abbott Laboratories has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Summary

Abbott Laboratories beats Organigram Global on 12 of the 14 factors compared between the two stocks.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.